Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach
Open Access
- 30 June 2025
- journal article
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (28) , 22336-22375
Abstract
This review covers the recent developments of synthetic routes of derivatization and anticancer activities of halogenated spirooxindoles scaffolds during 2020–2025, highlighting the molecular targets.Keywords
Funding Information
- Alexander von Humboldt-Stiftung
- University of Sharjah (Seed Research Project No. (24021440154))
- Prince Sultan University
This publication has 104 references indexed in Scilit:
- Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical SuccessJournal of Medicinal Chemistry, 2009
- Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2Journal of Molecular Graphics and Modelling, 2009
- Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancerMolecular Cancer Therapeutics, 2008
- A quantitative analysis of kinase inhibitor selectivityNature Biotechnology, 2008
- A Pharmacophore Map of Small Molecule Protein Kinase InhibitorsJournal of Chemical Information and Modeling, 2007
- Natural Health Products That Inhibit Angiogenesis: A Potential Source for Investigational New Agents to Treat Cancer—Part 1Current Oncology, 2006
- Protein flexibility and drug design: how to hit a moving targetCurrent Opinion in Chemical Biology, 2002
- 2.2 Å refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MnATP and a peptide inhibitorActa Crystallographica Section D Structural Biology, 1993
- Structural Framework for the Protein Kinase FamilyAnnual Review of Cell Biology, 1992
- Crystal Structure of the Catalytic Subunit of Cyclic Adenosine Monophosphate-Dependent Protein KinaseScience, 1991